Loading...
Crucell Announces PER.C6® Licensing Agreement with Tibotec
25-Nov-2005
Advertisement
Dutch biotechnology company Crucell N.V. announced that it has signed a PER.C6® license agreement with Ireland-based Tibotec Pharmaceuticals Ltd. The non-exclusive agreement allows Tibotec to use the PER.C6® cell line for research in the field of virology.
Under the terms of the agreement, Tibotec will pay a research license fee, annual maintenance fees and milestone payments. Further financial details were not disclosed.